Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A, C, W-135 and Y conjugate vaccine (Sanofi, c5290a)
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A quadrivalent meningococcal conjugate vaccine (MenACWY) is a biologic vaccine designed to provide active immunization against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W-135, and Y. Unlike older polysaccharide vaccines, the conjugate formulation chemically links the capsular polysaccharides of the bacteria to a carrier protein (such as CRM197, tetanus toxoid, or diphtheria toxoid). This conjugation converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, inducing immunological memory, higher antibody titers, and longer-lasting protection across all age groups, including infants. It also has the potential to reduce nasopharyngeal carriage of the bacteria, thereby contributing to herd protection.
- Brand names
- MenveoMenactraNimenrixMenQuadfi
- Other names
- quadrivalent ACWY meningococcal conjugate vaccineMenACWY conjugate vaccinequadrivalent meningococcal conjugate vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)TCR-CRM197/DT (T-cell receptor (TCR) recognizing CRM197 or diphtheria toxoid peptides presented on MHC class II)
Beyond the preview
Go deeper on meningococcal group A, C, W-135 and Y conjugate vaccine (Sanofi, c5290a).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A, C, W-135 and Y conjugate vaccine (Sanofi, c5290a).